Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Alzheimer s Disease · Mild Cognitive Impairment (MCI)
De qué trata este estudio
El registro no identifica actualmente este estudio como reclutando. Consulta su estado antes de planificar una evaluación.
- Tipo de estudio
- Observacional
- Fase
- No aplica / no indicada
- Rango de edad
- 40 años - No especificado
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- Aceptados
- Participantes
- 1600 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
Population aging is transforming the epidemiological landscape of the Asia-Pacific region at an unprecedented pace. By 2050, more than one quarter of the region's population will be aged over 60, with 36.7% of countries projected to become" super-aged" societies.
Within Hong Kong specifically, the age- and gender-adjusted prevalence rates of mild and major neurocognitive disorder (NCD) among adults aged 60 years or above have been estimated at 21.8% and 9.7%, respectively. The scale of this burden intensifies considerably within institutional care environments, where roughly seven in ten long-term care (LTC) residents have been identified as having major NCD. Recent local survey data also indicate that severe cognitive impairment affects up to 49.8% of residents aged above 85 years. Given current demographic trajectories, the number of individuals living with dementia in Hong Kong is projected to triple over the next two decades. These trends underscore an urgent, time-sensitive need for scalable, accurate, and population-appropriate tools for the early detection and prognostic stratification of cognitive impairment, tools that must be actionable at the point of care and deployable at population scale.
This study aim to generate a large database of cognitive, neuroimaging, plasma biomarkers, lifestyle and psychological information of the subjects who suffered from neurocognitive disorders
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria:
1. Aged ≥ 40 years old; and
2. Participants must have a study partner (spouse, relative, or other person in regular contact, ≥ 10 hours/week)who is willing and able to accompany participant to relevant visits and provide independent report on cognitive/functional/behavioral status (e.g., cognitive evaluation); and
3. Visual and auditory acuity sufficient (with correction/hearing aids as needed) to complete neuropsychological testing as per examiner judgment; and
4. A primary language of Cantonese.
Exclusion Criteria:
1. Clinical diagnosis of a primary neurological disorder that could independently account for cognitive impairment, including but not limited to Huntington's disease, normal pressure hydrocephalus, prion disease (CJD or variants), multiple sclerosis or other demyelinating disease, epilepsy, and/or
2. Know history of major depressive episodes, schizophrenia, bipolar disorder, and/or
3. Know history of moderate-to-severe traumatic brain injury, brain tumor, and/or
4. Contraindication for MRI or PET.
Población del estudio
Subjects will be identified from community, existing cohorts and specialist clinics
Entiende la evaluación inicialTratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- No informado
- Enmascaramiento
- No informado
Cognitive Unimpaired
No informado en este registro.
MCI
Subject with mild cognitive impairment, which identified with CDR =0.5
Dementia
Subject with mild cognitive impairment, which identified with CDR =1
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Hong Kong Montreal Cognitive Assessment (HK-MoCA)
Plazo: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
The HK-MoCA is a locally validated, brief cognitive screening tool assessing multiple domains including attention, executive function, memory, language, visuospatial ability, and orientation, and is widely used to detect mild cognitive impairment in the Hong Kong Chinese population. The total score is 30. The lower the score, the higher risk of cognitive impairment
Clinical Dementia Rating
Plazo: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
The CDR is a semi-structured interview-based staging instrument that evaluates both cognitive and functional performance across six domains (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care), yielding a global score that reflects overall severity of cognitive impairment (0 = normal, 0.5 = questionable/very mild, 1 = mild, 2 = moderate, 3 = severe).
Hong Kong List Learning Test
Plazo: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
The HKLLT is a culturally adapted verbal list-learning test modeled after the California Verbal Learning Test, used to assess verbal learning and memory, with Trial 4 (T4, delayed recall) serving as a sensitive index of episodic memory decline. The lower the standard deviation of the Trial 4 recall, the higher the risk of cognitive impairment
Simple Mild Neurocognitive Disorder due to Alzheimer's Disease Risk Test (SMART)
Plazo: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
The SMART is a novel digitalised tool that incorporates both subjective and objective measures of cognitive impairment. it incorporates immediate recall, delayed recall, and verbal fluency tasks. The lower the z-score, the higher the risk of cognitive impairment
Medidas secundarias
The pathological findings and changes in SUVR on PET imaging
Plazo: baseline and 3 year follow up
An amyloid PET (Positron Emission Tomography) scan measures beta-amyloid plaques in the brain which lead to Alzheimer's disease (AD) pathogenesis. One of the key quantitative measurements is Standarized uptake value ratio (SUVR) . The higher the value of SUVR reflect greater amyloid accumulation in the brain.
The pathological findings and changes on MRI
Plazo: baseline and 3 year follow up
A MRI brain scan mainly investigate and measure the structure of the brain. Volume of specific brain regions (such as the hippocampus, ventricles, or total gray/white matter) in cubic centimeters (cm³)
The pathological findings and changes in Centiloid Scale on PET imaging
Plazo: baseline and 3 year follow up
An amyloid PET (Positron Emission Tomography) scan measures beta-amyloid plaques in the brain which lead to Alzheimer's disease (AD) pathogenesis. Another key quantitative measurement is Centiloid Scale (CL) . The higher the value of CL reflect greater amyloid accumulation in the brain.
Otras medidas
Blood biomarkers
Plazo: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
Biomarkers will include molecular and cellular assays, genomic, epigenomic, and other multi-omic assays for both cellular and acellular fractions.
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (1)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
1 centros
The Chinese University of Hong KongHong Kong, ChinaEstado desconocido
Equipo y fechas
- Patrocinador principal
- Chinese University of Hong Kong
- Inicio del estudio
- 30 nov 2026 Estimado
- Finalización primaria
- 31 dic 2031 Estimado
- Finalización del estudio
- 30 jun 2032 Estimado
- Primera publicación
- 4 nov 2026 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026